This is the authors' abstract. We don't add key points for this paper.
Drug-drug interactions influence drug efficacy and patient prognosis, providing substantial research value. Some existing methods struggle with the challenges posed by sparse networks or lack the capability to integrate data from multiple sources. In this study, we propose MOLGAECL, a novel approach based on graph autoencoder pretraining and molecular graph contrastive learning. Initially, a large number of unlabeled molecular graphs are pretrained using a graph autoencoder, where graph contrastive learning is applied for more accurate representation of the drugs. Subsequently, a full-parameter fine-tuning is performed on different data sets to adapt the model for drug interaction-related prediction tasks. To assess the effectiveness of MOLGAECL, comparison experiments with state-of-the-art methods, fine-tuning comparison experiments, and parameter sensitivity analysis are conducted. Extensive experimental results demonstrate the superior performance of MOLGAECL. Specifically, MOLGAECL achieves an average increase of 6.13% in accuracy, 6.14% in AUROC, and 8.16% in AUPRC across all data sets.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Li et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: